NAPSRX/CNPR EXAM: REVISED 18TH
EDITION | VERIFIED STYLE, (LATEST
UPDATE 2026/2027) WITH
CORRECT/ACCURATE ANSWERS
National Association of Pharmaceutical Sales Representatives (NAPSRx) and the Certified
National Pharmaceutical Representative (CNPR) certification offered by the association
1. What does a STAT order mean?
A. A drug given daily
B. A drug given PRN
C. A drug needed immediately and given only once
D. A drug given at bedtime
🟨 Correct Answer: C
,Rationale:
STAT is derived from Latin statim, meaning immediately. It is used for urgent, often life-saving situations
and is typically administered once, without delay.
2. What information does the overdosage section of drug labeling
provide?
A. Drug interactions
B. Dosage adjustments
C. Signs, symptoms, and treatment of acute overdoses
D. Pharmacokinetics
🟨 Correct Answer: C
Rationale:
FDA labeling requires overdose sections to address toxicity, including clinical symptoms and appropriate
emergency treatment.
3. Types of drug-drug interactions include:
A. Absorption, distribution, metabolism
B. Duplication, opposition (antagonism), and alteration
C. Potency, efficacy, safety
D. Synergism only
🟨 Correct Answer: B
Rationale:
Interactions may cause duplicate therapy, antagonistic effects, or altered drug action via metabolism or
absorption changes.
4. Tolerance vs. resistance is best described as:
A. Both are allergic responses
B. Tolerance is genetic; resistance is learned
C. Tolerance is diminished response; resistance is cellular ability to resist drug effects
D. Both refer to overdosing
🟨 Correct Answer: C
,Rationale:
Tolerance develops in patients over time, while resistance occurs at the cellular or microbial level,
especially with antibiotics.
5. An Abbreviated New Drug Application (ANDA) requires
manufacturers to:
A. Repeat Phase III trials
B. Demonstrate bioequivalence to the innovator drug
C. Prove superior efficacy
D. Submit international data
🟨 Correct Answer: B
Rationale:
ANDA approval avoids duplicate testing by requiring bioequivalence, ensuring the generic performs the
same as the brand drug.
6. The Hatch-Waxman Act of 1984 is also known as:
A. FDA Modernization Act
B. Orphan Drug Act
C. Drug Price Competition and Patent Restoration Act
D. Controlled Substances Act
🟨 Correct Answer: C
Rationale:
Hatch-Waxman encourages generics while protecting innovation through patent extensions and 30-month
stays.
7. Which transport mechanism requires energy (ATP)?
A. Passive diffusion
B. Facilitated diffusion
C. Active transport
D. Osmosis
🟨 Correct Answer: C
, Rationale:
Active transport moves substances against a concentration gradient, requiring cellular energy.
8. Potency vs. efficacy is best defined as:
A. Potency is safety; efficacy is dose
B. Potency is amount needed; efficacy is maximum effect
C. Both measure toxicity
D. Efficacy is less important
🟨 Correct Answer: B
Rationale:
A drug may be potent but ineffective. Efficacy—the maximum effect—is more clinically important.
9. The four phases of clinical trials are:
A. Discovery, safety, efficacy, review
B. Phase A–D
C. Phases I–IV
D. Preclinical only
🟨 Correct Answer: C
Rationale:
Phase I (safety), Phase II (efficacy), Phase III (large-scale), Phase IV (post-marketing).
10. Key parts of a clinical paper include all EXCEPT:
A. Abstract
B. Methods
C. Results
D. Sales analysis
🟨 Correct Answer: D
Rationale:
Clinical papers follow IMRAD format and exclude commercial content.
EDITION | VERIFIED STYLE, (LATEST
UPDATE 2026/2027) WITH
CORRECT/ACCURATE ANSWERS
National Association of Pharmaceutical Sales Representatives (NAPSRx) and the Certified
National Pharmaceutical Representative (CNPR) certification offered by the association
1. What does a STAT order mean?
A. A drug given daily
B. A drug given PRN
C. A drug needed immediately and given only once
D. A drug given at bedtime
🟨 Correct Answer: C
,Rationale:
STAT is derived from Latin statim, meaning immediately. It is used for urgent, often life-saving situations
and is typically administered once, without delay.
2. What information does the overdosage section of drug labeling
provide?
A. Drug interactions
B. Dosage adjustments
C. Signs, symptoms, and treatment of acute overdoses
D. Pharmacokinetics
🟨 Correct Answer: C
Rationale:
FDA labeling requires overdose sections to address toxicity, including clinical symptoms and appropriate
emergency treatment.
3. Types of drug-drug interactions include:
A. Absorption, distribution, metabolism
B. Duplication, opposition (antagonism), and alteration
C. Potency, efficacy, safety
D. Synergism only
🟨 Correct Answer: B
Rationale:
Interactions may cause duplicate therapy, antagonistic effects, or altered drug action via metabolism or
absorption changes.
4. Tolerance vs. resistance is best described as:
A. Both are allergic responses
B. Tolerance is genetic; resistance is learned
C. Tolerance is diminished response; resistance is cellular ability to resist drug effects
D. Both refer to overdosing
🟨 Correct Answer: C
,Rationale:
Tolerance develops in patients over time, while resistance occurs at the cellular or microbial level,
especially with antibiotics.
5. An Abbreviated New Drug Application (ANDA) requires
manufacturers to:
A. Repeat Phase III trials
B. Demonstrate bioequivalence to the innovator drug
C. Prove superior efficacy
D. Submit international data
🟨 Correct Answer: B
Rationale:
ANDA approval avoids duplicate testing by requiring bioequivalence, ensuring the generic performs the
same as the brand drug.
6. The Hatch-Waxman Act of 1984 is also known as:
A. FDA Modernization Act
B. Orphan Drug Act
C. Drug Price Competition and Patent Restoration Act
D. Controlled Substances Act
🟨 Correct Answer: C
Rationale:
Hatch-Waxman encourages generics while protecting innovation through patent extensions and 30-month
stays.
7. Which transport mechanism requires energy (ATP)?
A. Passive diffusion
B. Facilitated diffusion
C. Active transport
D. Osmosis
🟨 Correct Answer: C
, Rationale:
Active transport moves substances against a concentration gradient, requiring cellular energy.
8. Potency vs. efficacy is best defined as:
A. Potency is safety; efficacy is dose
B. Potency is amount needed; efficacy is maximum effect
C. Both measure toxicity
D. Efficacy is less important
🟨 Correct Answer: B
Rationale:
A drug may be potent but ineffective. Efficacy—the maximum effect—is more clinically important.
9. The four phases of clinical trials are:
A. Discovery, safety, efficacy, review
B. Phase A–D
C. Phases I–IV
D. Preclinical only
🟨 Correct Answer: C
Rationale:
Phase I (safety), Phase II (efficacy), Phase III (large-scale), Phase IV (post-marketing).
10. Key parts of a clinical paper include all EXCEPT:
A. Abstract
B. Methods
C. Results
D. Sales analysis
🟨 Correct Answer: D
Rationale:
Clinical papers follow IMRAD format and exclude commercial content.
